China is trying to make the transfer of personal healthcare data out of China more regulated and formal. Unlike other Asian markets, tissue and blood samples cannot be sent outside of China for analysis. However, personal healthcare data can be sent overseas if certain requirements are met. The measures for security assessment for cross-border data transfers were concluded on July 7. Foreign medical companies should create a dedicated entity or choose a China representative to inform the appropriate government jurisdiction with respect to the healthcare information they accumulate. If foreign healthcare companies do not do this, they can be ostracized and penalized. This law also gives Chinese citizens more rights with Informed consent, outlines data violations, data processing conformity, etc. Restrictions on the amount of data transferred are also discussed.
Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
Mr. Gross founded PBM in 1988 and has helped hundreds of medical companies with regulatory and business development issues in Asia. He is recognized nationally and internationally as a leader in the Asian medical markets. Mr. Gross has a BA degree, Phi Beta Kappa, from the University of Pennsylvania and an MBA from Columbia University.
Source used in the article: https://www.morganlewis.com/pubs/2022/07/china-data-privacy-laws-and-implications-for-healthcare-industry